Wockhardt Ltd. on Monday announced its Q2 FY2021 results. The company reported a net profit of Rs 3.29 crore for the September quarter, a 100% growth YoY. It had posted a loss of Rs 94.24 crore in the corresponding quarter previous year.
The pharmaceutical posted a total income of Rs 730.29 crore during the Q2 FY2021 period as compared to Rs 682.69 crore during the FY2020 period. In the previous quarter, it posted Rs 606.22 crore revenue.
The Mumbai based company has reported diluted Earnings per Share (EPS) of Rs 0.32 for the period. It had posted EPS of Rs 68.37 for the previous Q1 June period.
The company stated in its BSE regulatory filing, “Profit after Tax (PAT) for H1FY21 is reported at Rs.764 crore as against Loss of Rs.127 crore in the corresponding period. The Profit includes Exceptional Items in connection with the transfer of the business comprising 62 products and line extensions along with related assets and liabilities, contracts, permits, intellectual properties, marketing, sales and distribution of the
same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives, and the manufacturing facility at Baddi, Himachal Pradesh, where some of the products which are being transferred were manufactured (together the “Business Undertaking”), to Dr. Reddy’s Laboratories Limited (“DRL”).”
